Breaking Finance News

Oppenheimer Holdings Inc. announced MEI Pharma Inc (NASDAQ:MEIP), bumping its target to $6.50 earlier today

Yesterday MEI Pharma Inc (NASDAQ:MEIP) traded -2.19% lower at $1.67. The company’s 50-day moving average is $2.84 and its 200-day moving average is $2.01. The last closing price is down 33.15% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time. 92,874 shares of MEIP traded, down from an avg. volume of 479,353

Oppenheimer Holdings Inc. raised the target price of MEI Pharma Inc (NASDAQ:MEIP) to $6.50 reporting a possible upside of 2.89%.

Recent Performance Chart


MEI Pharma Inc has PE ratio of 78.82 with a one year low of $1.34 and a one year high of $3.26 and has a market capitalization of $0.

A total of 1 firm has issued a report on the stock. 0 equity analysts rating the company a strong buy, zero equity analysts rating the company a buy, 0 brokers rating the stock a hold, 0 analysts rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $7.00.

General Company Details For MEI Pharma Inc (NASDAQ:MEIP)

MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.